ENDRA Life Sciences Stock Forecast, Price & News

ENDRA Life Sciences' stock was trading at $1.0029 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NDRA shares have decreased by 30.2% and is now trading at $0.70.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ENDRA Life Sciences.

ENDRA Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for ENDRA Life Sciences.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.07.
View ENDRA Life Sciences' earnings history.

1 brokers have issued 12 month price objectives for ENDRA Life Sciences' shares. Their forecasts range from $6.00 to $6.00. On average, they expect ENDRA Life Sciences' stock price to reach $6.00 in the next year. This suggests a possible upside of 757.1% from the stock's current price.
View analysts' price targets for ENDRA Life Sciences.

Some companies that are related to ENDRA Life Sciences include Fc Global Realty (FCRE), IRIDEX (IRIX), Helius Medical Technologies (HSDT), Helius Medical Technologies (HSDT), Second Sight Medical Products (EYES), Reshape Lifesciences (RSLS), Precision Optics (PEYE), Digirad (DRAD), Viveve Medical (VIVE), Micron Solutions (MICR), Vaso (VASO), Guided Therapeutics (GTHP), ReShape Lifesciences (RSLSD), Non-Invasive Monitoring Systems (NIMU) and Aradigm (ARDMQ).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Ampio Pharmaceuticals (AMPE), BioNano Genomics (BNGO), Opko Health (OPK), TherapeuticsMD (TXMD), Vista Gold (VGZ), electroCore (ECOR) and Genocea Biosciences (GNCA).

(NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NDRA stock can currently be purchased for approximately $0.70.

ENDRA Life Sciences has a market capitalization of $17.42 million and generates $10,000.00 in revenue each year. The company earns $-13,310,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. ENDRA Life Sciences employs 15 workers across the globe.

The official website for ENDRA Life Sciences is www.endrainc.com.

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]